We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GE Healthcare and BAC Announce Collaboration

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GE Healthcare and BAC Announce Collaboration "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

GE Healthcare, a unit of General Electric Company and BAC BV, the Bio Affinity Company, have announced that they have entered into a strategic collaboration in the affinity ligand and chromatographic media area.  

Under the terms of the agreement, the two companies will develop affinity chromatography media for human antibodies and adeno-associated virus (AAV) viral vector purification.

The first products are expected to be commercially available during 2007 through GE Healthcare’s Custom Designed Media business. 

The collaboration is expected to generate several affinity chromatography media solutions for biopharmaceutical manufacture and drug discovery research.

"This collaboration will allow us to expand our current range of ligand technologies and libraries, enabling us to develop more efficient purification processes for our customers in biopharmaceutical manufacturing," said Ann O’Hara, General Manager of BioProcess for GE Healthcare.

"As a well established market leader, GE Healthcare is the perfect partner for us," said Dr. Laurens Sierkstra, CEO of BAC. 

"This Agreement underlines their confidence in our  CaptureSelect® products and clearly validates our technology as a giant step forward in the purification of pharmaceutical products."